Immunotherapy has been one of the most transformative treatments for cancer patients in recent decades, shifting the emphasis ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today presented new data from the first clinical study in Alzheimer's disease ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Please provide your email address to receive an email when new articles are posted on . More than 7% of patients receiving immune checkpoint blockade therapy and antibiotics developed immune-related ...

or on the link below. Immune checkpoint inhibitors (ICIs) are shown to be effective among patients with metastatic colorectal cancer (mCRC) harboring high microsatellite instability (MSI-H) and/or ...

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish The following represents disclosure ...

Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of “non-self” tumor cells. However, in chronic ...